

Application and claims data<sup>1</sup>

May 31, 2024

World Bank Region	Number of Applications/enquiries received <sup>2</sup>	Numbers of Applications received where a COVAX-distributed Vaccine was administered	Number of Applications Compensated <sup>3*</sup>
<i>East Asia &amp; Pacific</i>	21	16	13
<i>Europe &amp; Central Asia</i>	30	0	0
<i>Latin America &amp; Caribbean</i>	42	0	0
<i>Middle East &amp; North Africa</i>	41	2	1
<i>North America</i>	11	0	0
<i>South Asia</i>	9	1	0
<i>Sub-Saharan Africa</i>	18	4	2
<b>TOTAL</b>	<b>172</b>	<b>23</b>	<b>16</b>

\* Of the 23 Applications where a COVAX distributed Vaccine was administered, 16 Applications **(69.6%) were found to be compensable**. Fifteen of these have already been compensated, and 1 has been offered compensation. Seven Applications were determined to be non-compensable.

<sup>1</sup> Capitalized terms used, but not defined, in this document have the meaning ascribed to such terms in the Program's Protocol. The data contained in this document will be updated from time to time, as needed.

<sup>2</sup> Not all Applications were completed with all necessary information.

<sup>3</sup> In accordance with the Program's Protocol, compensation (for death or total or partial permanent Impairment) is calculated based on the following methodology:

- GDP per capita of the Relevant AMC Eligible Economy x 12 x the harm factor resulting from the (COVAX-distributed) Vaccine or its administration; and
- a daily in-Hospital benefit of USD 100.00 per day for each day of Hospitalization or prolongation of existing Hospitalization, if any, not to exceed a maximum payment period of 60 days.

The GDP per capita of the relevant AMC Eligible Economy is as per the most recently published World Bank threshold as at the time of the Payment is approved; and

The harm factors resulting from the COVAX distributed Vaccine or its administration range from 0.1 to 1.5. The harm factors can be found in Section 9 of the Program's Protocol ([COVAX-Compensation-Program-Protocol.pdf \(covaxclaims.com\)](#)).

## Timeline to Process Applications where a COVAX-Distributed Vaccine was Administered<sup>4</sup>

**May 31, 2024**

<b>World Bank Region</b>	<b>Average number of days from Application submission date to compensability decision date (months)</b>	<b>Average number of days from Application submission date to Payment date (months)<sup>5</sup></b>
<i>East Asia &amp; Pacific</i>	176 (5.9)	236 (7.9)
<i>Europe &amp; Central Asia</i>	NA	NA
<i>Latin America &amp; Caribbean</i>	NA	NA
<i>Middle East &amp; North Africa</i>	137 (4.6)	149 (4.9)
<i>North America</i>	NA	NA
<i>South Asia</i>	37 (1.2)	NA
<i>Sub-Saharan Africa</i>	169 (5.6)	301 (10.0)
	<b>165.6 (5.5)</b>	<b>239 (8.0)</b>

<sup>4</sup> Capitalized terms used, but not defined, in this document have the meaning ascribed to such terms in the Program's Protocol. The data contained in this document will be updated from time to time, as needed.

<sup>5</sup> The average number of days from Application submission date to Payment date only applies to the Applications that were determined to be compensable.

- In accordance with the Program's Protocol, the Program Administrator is bound by short response timelines at each stage of the Application process.
- In cases where delays were encountered in receiving the required information, medical records and/or other documents from Claimants, the overall process took longer to complete.